Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene Begins Phase 2 Neoadjuvant Muzastotug in CRC
Details : ADG126 (muzastotug) is a fully human anti-CTLA-4 SAFEbody. It is under development for metastatic microsatellite-stable colorectal cancer.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene to Present Muzastotug + KEYTRUDA® Data at ASCO GI Symposium
Details : ADG126 (muzastotug) is a fully human anti-CTLA-4 SAFEbody. It is under development for metastatic microsatellite-stable colorectal cancer.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer
Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : AMP945,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene Expands Collaboration Program for ADG126 with KEYTRUDA® Efficacy
Details : ADG126 (muzastotug) is a human anti-CTLA-4 SAFEbody, designed for specific target binding, under development for metastatic microsatellite-stable colorectal cancer.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
September 02, 2024
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clearance of Amplia's IND for Pancreatic Cancer Trial in US
Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene Presents Data on ADG126 Combined with Pembrolizumab in MSS Colorectal Cancer
Details : ADG126 (muzastotug) is a masked anti-CTLA-4 SAFEbody. It is currently being evaluated in phase 1/2 clinical trials for the treatment of microsatellite-stable colorectal cancer.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADG126 is a fully human anti-CTLA-4 SAFEbody designed to mask the antibody binding site of ADG126, which would be unmasked in the TME, where activated ADG126 would block CTLA-4 and deplete regulatory T-cells by means of ADCC.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in Model of Pancreatic Cancer
Details : AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2023
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : CSIRO
Deal Size : Undisclosed
Deal Type : Collaboration
Amplia Receives Grant to Collaborate with CSIRO – Supplementary Announcement
Details : The research collaboration with CSIRO will help to develop formulations of its small molecule FAK inhibitors, including AMP945 that could be applied topically to wounds and burns to aid healing and reduce scarring.
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : AMP945
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : CSIRO
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AMP945,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the development of novel masked antibody-drug conjugate (ADC) candidates, including ADG126 leveraging Adagene’s proprietary SAFEbody precision masking technology.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : $12.1 million
April 05, 2023
Lead Product(s) : AMP945,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Collaboration